Abstracts tagged "Lupus and antimalarial drugs"

Abstract Number: 2924 • 2017 ACR/ARHP Annual Meeting
Effect of Antimalarials over the Different Domains of the Damage INDEX in Latin American SLE Patients
Guillermo J. Pons-Estel¹, Daniel Wojdyla², Graciela S. Alarcón³, Rosa Maria Serrano⁴, Rosana Quintana⁴, Manuel Ugarte-Gil⁵, Victor Pimentel-Quiroz⁵, Enrique R Soriano⁶, Marina Scolnik⁷, Monica Sacnun⁴, José A. Gómez-Puerta⁸, Mario H. Cardiel⁹, Virginia Pascual-Ramos¹⁰, Ignacio Garcia de la Torre¹¹, Leonor Barile⁹, Luis H. Silveira¹², Mary Carmen Amigo¹³, Maria Josefina Sauza del Pozo¹⁴, Marlene Guibert-Toledano¹⁵, Gil A. Reyes¹⁶, Antonio Iglesias Gamarra¹⁷, Luis Alonso Gonzalez¹⁸, Rosa Chacón-Díaz¹⁹, Maria H Esteva Spinetti²⁰, Isaac Abadi²⁰, Eduardo M. Acevedo-Vásquez²¹, Jose Alfaro-Lozano²², Maria Ines Segami²³, Loreto Massardo²⁴, Oscar Neira²⁵, Emilia Sato²⁶, Eloisa Bonfa²⁷, Lilian Costallat²⁸, Ricardo Xavier²⁹, Fernando Cavalcanti³⁰, Nilizio A. Da Silva³¹, Eduardo Ferreira Borba³², Luis J. Catoggio³³, Joao C. Tavares Brenol²⁹, Verónica Saurit³⁴, Francisco Caeiro³⁵, Alejandro Alvarellos³⁴, Judith Sarano³⁶, Mercedes Garcia³⁷, Laura Onetti³⁸, Cristina Drenkard³⁹, Guillermo Berbotto⁴⁰, Hugo R. Scherbarth⁴¹, Sergio Jacobelli²⁴, Jose F Molina⁴², Gloria Vásquez⁴² and Bernardo Pons-Estel⁴³, ¹GLADEL, Rosario, Argentina, ²GLADEL consultant, Rosario, Argentina, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Argentina, GLADEL, Rosario, Argentina, ⁵Peru, GLADEL, Lima, Peru, ⁶Argentina, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁷Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina, ⁸Colombia, GLADEL, Medellín, Colombia, ⁹GLADEL, Mexico, Mexico, ¹⁰Instituto Nacional de Ciencias Médicas y Nutrició, Mexico City, Mexico, ¹¹Hospital General de Occidente, Guadalajara, Mexico, ¹²Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City DF, Mexico, ¹³Centro Medico ABC, Mexico, Mexico, ¹⁴Servicio de Reumatología, Instituto Mexicano de Seguro Social, Hospital de Especialidades Nº 25, Monterrey, Mexico, ¹⁵Centro de Investigaciones Médico Quirúrgicas, Habana, Centro de Investigaciones Médico Quirúrgicas, Habana, La Habana, Cuba, ¹⁶GLADEL, Havana, Cuba, ¹⁷Grupo de Inmunología Celular e Inmunogenética, Facultad de Medicina, Universidad de Antioquia, medellin, Colombia, ¹⁸Medicarte IPS, Medellín, Colombia, ¹⁹Servicio de Reumatología, Hospital Universitario de Caracas, Centro Nacional de Enfermedades Reumáticas, Caracas, Venezuela, ²⁰GLADEL, Caracas, Venezuela (Bolivarian Republic of), ²¹Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, ²²Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ²³GLADEL, Lima, Peru, ²⁴GLADEL, Santiago, Chile, ²⁵Rheumatology Unit, Hospital del Salvador. Facultad de Medicina. Universidad de Chile, Santiago, Chile, ²⁶Rheumatology Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ²⁷Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²⁸GLADEL, Brazil, Brazil, ²⁹GLADEL, Porto Alegre, Brazil, ³⁰GLADEL, Pernambuco, Brazil, ³¹GLADEL, Goias, Brazil, ³²Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³³Rheumatology Unit, Internal Medicine Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³⁴Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ³⁵Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ³⁶Rheumatology Unit, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ³⁷Rheumatology, HIGA General San Martin La Plata, La Plata, Argentina, ³⁸GLADEL, Cordoba, Argentina, ³⁹Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁴⁰Sanatorio Británico, Rosario, Argentina, ⁴¹GLADEL, Mar del Plata, Argentina, ⁴²GLADEL, Medellin, Colombia, ⁴³GLADEL, Rosario, Santa Fe, Argentina
Background/Purpose: We have previously shown that Latin American SLE patients treated with Antimalarials (AMs) have a 25% lower risk of damage accrual than patients not…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].